Premium
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia
Author(s) -
Mohr Brigitte,
Schetelig Johannes,
SchäferEckart Kerstin,
Schmitz Norbert,
Hänel Mathias,
Rösler Wolf,
Frickhofen Norbert,
Link Hartmut,
Neubauer Andreas,
Schuler Ulrich,
Platzbecker Uwe,
Middeke Jan M.,
Ehninger Gerhard,
Bornhäuser Martin,
Schaich Markus,
Stölzel Friedrich
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12253
Subject(s) - medicine , hazard ratio , chemotherapy , hematopoietic stem cell transplantation , transplantation , confidence interval , oncology , prospective cohort study , proportional hazards model , induction chemotherapy , surgery , gastroenterology
Summary The role of allogeneic stem cell transplantation ( HSCT ) as compared to chemotherapy in acute myeloid leukaemia ( AML ) patients with abnormalities of chromosome 17p [abnl(17p)] has not yet been defined. Therefore, we analysed 3530 AML patients treated in three randomized, prospective, controlled clinical trials and compared post‐remission therapies using a multivariate C ox regression analysis to determine whether allogeneic HSCT is superior than chemotherapy in overcoming the detrimental impact of patients with abnl(17p) AML . One hundred and forty‐three patients (4%) were identified with abnl(17p) AML . All patients had received intensive induction chemotherapy. Forty‐seven patients with a median age of 54 years (18–69 years) proceeded to allogeneic HSCT in first or second remission. The 3‐year overall survival ( OS ) rate for the entire cohort of patients was 4% [95% confidence interval ( CI ), 1–7%]. OS and event‐free survival at 3 years, calculated from the day of HSCT , was 11% (95% CI , 2–20%) and 6% (95% CI , 0–13%), respectively. Multivariate C ox regression analysis showed no benefit of allogeneic HSCT compared to chemotherapy (Hazard Ratio 0·97, 95% CI 0·56–1·67, P = 0·9). In conclusion, allogeneic HSCT does not improve survival in patients with abnl(17p) AML as compared to other adverse cytogenetic risk abnormalities.